





























Criterion	Evidence	Criterion Met?	
Strength of association	A recent rajidemiologic study from French Polynesia suggests a strong asso- cation between prestal Za's vius infection and microcephuly (estimat- ed risk ratio, approximately 50). ³ The substantial increase in the number of cases of microcephuly and other bera nanomalies that have been associated with the Zika virus outbreak in Braz's suggests a strong association. ³	Yes	
Consistency	Two epidemiologic studies, one from Brazil and one from French Poly- nesia, ¹⁴ support that sosciulizon between prenatal Zika virus infection and microcephilay and other senior brain anomalexialy after out- breaks of Zika virus infection in Brazil and French Polymsia, as well as preliminary reports of cases in Colombia, support consistency. ^{16,00} Case reports of Laivius infection in fetusas or infants with microcephily or other brain anomalies who were born to mothers who traveled to areas of active Zika virus franctions in upport consistency. ^{16,100}	Yes	TV NEW ENGLAND JOURNAL & NEDICINE
Specificity	Other causes of microcephaly exist; however, on the basis of clinical descrip- tions that are available for a small number of infants with presumed con- genital Zika virus infection," the clinical phenotype linked to the Zika vir- rus appears to be an unusual form of microcephaly that is consistent with the fetal brain disruption sequence.	Yes	SPECIAL REPORT
Temporality	Zika virus infection in mothers during pregnancy precedes the finding of mi- crocephaly or other brain anomalies in fetuses or infants. ¹⁴⁰ Zika virus outbreaks in Brazil and French Polynesia preceded the increase in the number of cases of microcephaly. ¹²	Yes	Zika Virus and Birth Detects — Reviewing the Evidence for Causality Sonja A. Rasmussen, M.D., Denie J. Jamieson, M.D., M.P.H., Manuret A. Hongin (P. D. M. P.H. and Jack P. Reterent M.D., M.P.H.
Biologic gradient	Infection is a phenomenon that is either present or absent; there is no dose- response relationship. No data are available regarding whether women with an increased viral load have a higher risk of adverse pregnancy or birth outcomes.	NA	magnetic net remeny characteristic and sign in constants make not inte
Plausibility	Findings are similar to those seen after prenatal infection with some other vi- ral teratogens (e.g., cytomegalowins and rubelia virus). ²⁴ Evidence that Zial arrus infects meal progenitor cells and produces cell death and abnormal growth, ²⁴ along with evidence of Zila virus in brains of fetuses and infants with microcephalo, on the basis of on immunohisi, tochemical staining and identification of Zila virus RNA and live vi- rus, ^{36,36,39} provides strong biologic plausibility.	Yes	This article was published on April 13, 2016, at NEJM.org.
Coherence	No results in an animal model of effects of Zika virus on prognancy have yet been published, but animal models have shown that Zika virus is neuro- trope, Z ^{asa} a funding that is consistent with prenatal Zika virus infection causing microcephaly and other brain anomalies. Zika virus infection and microcephaly.	Yes	
Experiment	No experimental animal model of Zika virus teratogenicity is available.	No	
Analogy	No other flavivirus has been shown to definitively cause birth defects in hu- mans, ⁶ but flaviviruses, Wesselsbron and japanese encephalitis viruses, have been shown to cause stilbirth and brain anomalies. ⁶ Findings are similar to those seen after prenatal infection with other viral te- catopers (e.g othoreagoivirus, holdla virus). ⁸	Yes	



American Headin Conganization World Health Organization America	Zika cases and reported by cou	l congenital syndrome associat untries and territories in the Am Cumulative cases Data as of March 2017		Provolonco		
Country/Territory	Zika Cases (Suspected/ Confirmed)	Confirmed congenital syndrome associated with Zika virus infectiond	Tx incidência Zika	Population X 10	Number of live births/year -	rate Microcephaly per 10,000 live birth
Brazil ¹⁴	346.475	2.386	165	209.553	3.084.620	7,7
Colombia ¹⁰	107.206	128	220	48.650	479.141	2,7
Dominican Republi	5.241	54	49	10.708	138.224	3,9
Guaternala ⁴	4.354	37	26	16.674	386.195	1,0
Martinique ⁷	36.701	22	9.268	396	5.441	40,4
French Guiana ⁷	10.803	17	3.914	276	6.247	27,2
Guadeloupe ⁷	31.227	14	6.616	472	5.758	24,3
Bolivia (Plurination	1.029	14	9,4	10.971	255.405	0,5
Puerto Rico ⁹	39.339	12	1.069	3.681	40.123	3,0
Panama ⁵	4.659	5	117	3.990	74.254	0,7
El Salvador ³	11.574	4	188	6.147	107.081	0,4
Costa Rica	7.874	2	161	4.881	78.486	0,3
Nicaragua	2.060	2	33	6.184	113.847	0,2
Paraguay ¹⁶	664	2	10	6.725	116.592	0,2
Honduras	32.403	2	396	8.190	193.775	0,1
Argentina ¹⁵	2.279	2	5	44.060	738.318	0,0
Saint Martin ⁷	3.415	1	9.486	36	627	15,9
Haiti ^e	2.960	1	27	10.916	249.212	0,0
Mexico ²	8.113	1	6	128.624	2.463.420	0,0









<section-header><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item>

Replication and Transmission of Flaviviruses

- 1. Virus transmitted to human in mosquito saliva
- 2. Virus replicates in target organs
- 3. Virus infects white blood cells and lymphatic tissues
- 4. Virus released and circulates in blood



Replication and Transmission Flaviviruses

- 5. Second mosquito ingests virus with blood
- Virus replicates

 mosquito midgut
 and other organs,
 infects salivary
 glands
- 7. Virus replicates in salivary glands



Prior Zika Virus Epidemics

2007 Micronesia

 An epidemic was reported in the Yap Islands, one of the 4 states in the Archipelago of Micronesia in the Pacific Ocean. Local and U.S. Researchers identified 185 suspected cases, of which 49 were confirmed and 59 were considered probable cases. It was estimated that 5050 of 6892 islanders > 3 years of age (73% of the population) was infected during the epidemic. The majority of subjects did not develop clinical illness.

2013 – French Polynesia

- In October of 2013, French Polynesia was in the midst of a serious dengue outbreak when health authorities idenfied Zika Virus cases. Over 8,500 cases were identified, with approximately 11% of the population affected. Forty cases of Guillain-Barré Syndrome were reported. Unclear how Zika reached the South Pacific.
- Until this outbreak, no serious consequences of Zika Virus had been reported. Other affected islands: Cook Island, Easter Island,, Vanuatu, Solomon Island and New Caledonia. Imported cases in Japan, Norway, France.













RAPID COMMUNICATIONS

Potential for Zika virus transmission through blood transfusion demonstrated during an outbreak in French Polynesia, November 2013 to February 2014

D Musso (dmusso@ilm.pf)¹, T Nhan¹, E Robin¹, C Roche¹, D Bierlaire¹, K Zisou¹, A Shan Yan¹, V M Cao-Lormeau¹, J Broult² Euro Surveill. 2014;19(14):pii=20761. Available online: http://www.eurosurveillance.org/

During the Zika virus outbreak in French Polynesia, 1505 asymptomatic blood donors were screened by molecular testing for ZIKAV viremia between November 2013 to February 2014: 42 (3%) were positive for ZIKAV. Blood banks should screen for ZIKAV in endemic areas.

PLOS | NEGLECTED TROPICAL DISEASES

> Transmission of Zika virus through breast milk and other breastfeeding-related bodily-fluids: A systematic review

April 10, 2017

Susannah Colt¹, Maria N. Garcia-Casal², Juan Pablo Peña-Rosas², Julia L. Finkelstein¹, Pura Rayco-Solon², Zita C. Weise Prinzo², Saurabh Mehta¹*









From dengue surveillance efforts a study began...

• Since 2012 at Fiocruz Manguinhos

pregnant women and their infants have been followed in a prospective cohort for the study of incidence of dengue in this population.

• In late 2015

following identification of ZIKV in Rio de Janeiro the cohort study was modified to actively screen for ZIKV by RT-PCR in blood and urine of pregnant women who presented with a rash within the last 5 days.











Zika Virus vs. Rubella Symptoms

- Arthralgias, predominantly of the hands and feet
- Edema of the hands and feet
- Low grade fever (≤ 38.5°C),
- Patchy erythema
- Pruritus
- Eye pain
- Conjunctival injection
- Dizziness
- Myalgias
- Posterior lymphadenopathy
- GI symptoms may occur, but are less frequent.

- Mild fever of 102 F (38.9 C) or lower
- Headache
- Conjunctival injection
- Enlarged, tender lymph nodes at the base of the skull, the back of the neck and behind the ears
- A fine, pink rash that begins on the face and quickly spreads to the trunk and then the arms and legs, before disappearing in the same sequence- often pruriginous
- Aching joints, especially in young women



ble	Z1KV-Positive Women (N = 134)	ZIKV-Negative Women (N = 73)	P Value)
Demographics		1000	COMPANY.
Are v			0.571
Median (IOR)	11/26-14	29 (25 5-14)	
Fione	16-46	12-41	
Other fursh members il	44/115 (18.3)	15/00/255.00	0.09
Better II. on hetelon 191	44/113 (38.5)	100 (23.0)	0.07
Partner III — Holytocal Hol (tip)	14/103 [13:6]	122 (7.3)	0.004
Use of repetient no rotal no. chi	44/90 (40.0)	57/63 (87.3)	0.000
History of dengue - no./total no. (%)	22/152 (Seral	Solea (Saro)	0.74
Socioeconomic status no./total.no. (%)}			
Income s2x minimum wage	48/308 [44.4]	28/63 (44.4)	1.0
Income >2 to s5x minimum wage	38/108 (35.2)	21/63 (33.3)	0.87
lincome >5× minimum wage	22/108 (20.4)	14/63 (22.2)	0.85
Week of gestation at time of infection			
Median (IQR)	24.5 (18-31)	27 (23-31)	0.23\$
Range	5-39	7-36	
Distribution mo. (%)			
0 to s13 wk	26 (29.4)	4 (5.5)	0.15
14 to ±28 wk	72 (53.7)	41 (56.2)	1.0
≥29 wk	36 (26.9)	28 (38.4)	0.45
Symptoms no./total no. (%)			
Rash¶			
Any	134/134 (100)	73/75 (100)	0.242
Median duration (IQR)	5 (4-7)	4 (3-6.5)	
Range	1-16	1-12	
Macular	57/134 (42.5)	37/75 (50.7)	0.31
Maculopapular	57/134 (42.5)	19/73 (26.0)	0.02
Other	20/134 (14.9)	17/73 (23.3)	0.38
Providus	116/129 (89.9)	64/73 (87.7)	0.64
Arthralgia or arthritis	81/130 (62.3)	51/73 (69.9)	0.29
Conjunctival injection	73/127 (57.5)	29/72 (40.3)	0.03
Headache	69(127 (54.3)	47/73 (64.4)	0.18
Fatigue or malaise	66/127 (52.0)	\$5(73(75.3)	0.002
Retro-orbital pain	53/131 (40.5)	29/73 (39.7)	1.0
Multia	51/130 (40.8)	43/69/67.3)	0.005
Lengtheteromethy	48/123 (38.4)	19(70/27.1)	0.12
Toralized	22/39 (56.4)	\$/10 (50.0)	0.74
Canandrad	17/19 (41.6)	5/10 (50.0)	0.74
	11/102 (10.4)	3010 (2004)	0.74
Parestresia	34/100 (34.0)	26/67 (36.8)	0.44
Edema	54(49 (54.5)	\$7/73 (50.7)	0.54
Pever, body temperature u37.5 °C	34/124 (27.4)	42/72 (58.3)	<0.001
Duration <24 fir	16(30(30.0)	12(23 (52.3)	1.0
Contraction and the set of the	militra (2010)	11/14/[47.3]	1.1

N ENGLY WED 37534 - NELWORK DECEMBER 35, 201







Fetus No.	Week of Gestation at Infection	Week of Gestation at Ultrasound Examination	Abnormal Findings on Doppler Ultrasonography	Findings at Birth
19	8	35	Microcephaly, cerebral calcifications, abnormal middle cerebral artery, intrauterine growth restriction	Microcephaly, cerebral calcifications on CT, global cerebral atrophy, macular lesions
40	8	20	Choroid plexus cyst, cerebellar atrophy (trans- verse diameter <5th percentile)	Still in utero
24	12	29	Microcephaly, cerebral calcification, Blake's cyst, agenesis vermis, club foot, intrauterine growth restriction	Still in utero
41	12	24	Mega cisterna magna (>95th percentile)	Still in utero
39	21	30	Cerebellar and cerebral right periventricular calcifications	Still in utero
17	22	26	Middle cerebral artery flow <sth percentile<="" td=""><td>Still in utero</td></sth>	Still in utero
12	22	27	Microcephaly, placental insufficiency as as- sessed by Doppler study, oligohydramnios, intrauterine growth restriction	Small for gestational age, head circumfer- ence proportional to body size, macular lesions
10	25	30	Normal first ultrasonogram, fetal death detected at 36 weeks on repeat ultrasonogram	Stillbirth
36	26	35	Microcephaly, abnormal umbilical artery flow (>95th percentile on the pulsatile index), intrauterine growth restriction	Small for gestational age, head circumfer- ence proportional to body size
38	27	35	Cerebral calcifications, ventriculomegaly, brachycephaly	Still in utero
2	30	34	None	Normal at birth
3	31	33	None	Normal at birth
53	32	38	Fetal death	Stillbirth
23	35	40	Anhydramnios, intrauterine growth restriction	Normal growth measure, poor sucking refler EEG abnormalities







26



Infant Outcomes	ZIKV- Exposed Live Infants (N=117) *	ZIKV-Unexposed Live Infants (N=57)	P Value*
Number of SGA babies	10/116 (8.6)	3/57 (5.3)	0.06
Number of Infants with Microcephaly	4/117 (3.4)	0/57	0.31
Number of Infants with Microcephaly*** Proportionate microcephaly Disproportionate microcephaly	2/117 (1.7) 2/117 (1.7)	0/57 0/57	1.0 1.0
Total number of adverse pregnancy outcomes Total number of adverse infant outcomes	5 8/125 (46.4) 49/117 (41.9)	7/ 61 (11.5) 3/57 (5.3)	<0.00 <0.00
Number of negative pregnancy outcomes by maternal trimester of infection (including fetal demise) First trimester Second trimester Third trimester	11/20 (55.0) 37/72 (51.4)* 10/34 (29.4)	3/4 (75.0) 2/35 (5.7) 2/22 (9.1)	<0.01 <0.01 <0.01

Birth Defe	ects Among Fei	Dec 2016 Tuses and Infants of US Wome	'n		
With Evide	ence of Possible	Zika Virus Infection During Pr	egnancy		
Margaret A. Honein, PhD Nina Ahmad, MD; Jennifi Carrie K. Shapiro-Mendo Philip Cavicchia, PhD; Sa ¹ Dana Meaney-Delman N	I: April L. Dawson, MPH; Emily E. Pe er Macdonald, MPH; Nicole Evert, N za, PhD; Titilope Oduyebo, MD; Anr My Slavinski, DVM; Jennifer L. White 4D- Denise I. Jamisson, MD; for the	tersen, MD; Abbey M, Jones, MPH; Ellen H, Lee, MD; Mahsa M, Yazdy, P S. Andrea Blingham, PhD; Sacchar, R. Ellington, MSPH; e D. Fine, MD; Catherine M, Brown, DVM; Jamie N, Sommer, MS; Jyod G MPH; S. Michele Wen; PhD; Ude R. Petersen, MD; Coleen Boyle, PhD; 16 78/a Breansave Besterie Caliboration	HQ; Supta, MPH;	10% rat defe	e of structural birth ects in registry
On April	Mor 4, 2017, this report was posted as ar	bidit <mark>v and Mortalitv Weeklv Report</mark> MMWR Early Relatse on the MMWR website (https://www.cdc.gov/mr	nwr).		
Vita and Evalua	al Signs: Update c ation of All U.S. In U.S. Zika	n Zika Virus–Associated Birth Defe fants with Congenital Zika Virus Ex Pregnancy Registry, 2016	ects (posure —	5% birth	a rate of structural defects in registry
	E	arly Release / June 8, 2017 / 66			
Characteristic	No. with brain abnormalities and/or microcephaly [¶]	No. with NTDs and early brain malformations, eye abnormalities, or consequence of CNS dysfunction without brain abnormalities or microcephaly	Total no. with ≥1 birth defect	Total no. of completed pregnancies	Percentage with Zika viru -associated birth defect (95% CI**)
Any laboratory eviden	ice of recent possible Zika viru	s infection ^{††}			
Fotal	108	14	122	2,549	5 (4-6)
Recent NAT-confirme	d Zika virus infection in mater	nal, placental, fetal, or infant specimen****			\frown
cecilit in the commune			80	1,508	5 (4-7)
otal	71	9	00		
Total	71 s or specimen collection date	9			
Total iming ⁵⁵⁵⁵ of symptome irst trimester ¹¹¹	71 s or specimen collection date 18	9 •••• 4	22	276	8 (5-12)
Total iming ⁸⁸⁸⁹ of symptom irst trimester ^{###} econd trimester ⁸⁸⁹	71 s or specimen collection date 18 34	9 **** 4 2	22 36	276 726	8(5-12) 5(4-7)

Table 4. Birth Outcomes and Abnormalities Observed in the	Fetuses and Infant	5. ⁰			
Variable		Time of ZIK	V Infection		
	First Trimester (N=189)	Second Trimester (N=252)	Third Trimester (N=114)	Total (N=S55)	
		no. of fetuses a	or infants (%)	100	
Birth outcome					
Stillborn or not carried to term	24 (12.7)	4 (1.6)	0	28 (5.0)	
Miscarried	11 (5.8)	0	0	11 (2.0)	
Not carried to term because of voluntary termination of pregnancy	1 (0.5)	0	0	1 (0.2)	
Not carried to term because of termination of pregnancy for medical reasons	9 (4.8)	1 (0.4)	0	10 (1.8)	
Stillborn	3 (1.6)	3 (1.2)	0	6 (1.1)	Structural CNS
Live-born	165 (87.3)	248 (98.4)	114 (100)	527 (95.0)	abnormalities
No prenatal ultrasonography after ZIKV infection ⁺	13 (6.9)	28 (11.1)	55 (48.2)	96 (17.3)	abriormantics
Abnormalities observed				\bigcirc	reported at birth 79
Neurologic or ocular birth defects:	24 (12.7)	9 (3.6)§	6 (5.3)	39 (7.0)	·
Microcephaly¶	19 (10.1)	8 (3.2)	5 (4.4)	32 (5.8)	
Severe	7 (3.7)	2 (0.8)	0	9 (1.6)	
Moderate: disproportionate	4 (2.1)	2 (0.8)	3 (2.6)	9 (1.6)	
Moderate: proportionate	8 (4.2)	4 (1.6)	2 (1.8)	14 (2.5)	
Intracranial calcifications	8 (4.2)	0	0	8 (1.4)	
Ventriculomegaly	7 (3.7)	1 (0.4)	0	8 (1.4)	
Lissencephaly	2 (1.1)	0	0	2 (0.4)	
Other brain abnormalities	8 (4.2)	1 (0.4)	0	9 (1.6)	
Neural-tube defects	1 (0.5)	0	0	1 (0.2)	
Eye abnormalities	0	0	0	0	
Consequences of central nervous system dysfunction	1 (0.5)	0	1 (0.9)	2 (0.4)	
Other birth defects	2 (1.1)	3 (1.2)	1 (0.9)	6 (1.1)	
Chromosomal defects	0	1 (0.4)	0	1 (0.2)	
Skeletal abnormalities	2 (1.1)	1 (0.4)	1 (0.9)	4 (0.7)	
Other	0	1 (0.4)	0	1 (0.2)	
Congenital 7ika syndrome	13 (6.9)	3 (1 2)	1 (0.9)	17.01	









30





Cell Zika Virus Infection during Pregnancy in Mice Causes Placental Damage and Fetal Demise















Zin et al, Jama Pediatrics



chorioretinal atrophy.

Eye Findings in Infants With Suspected or Confirmed Antenatal Zika Virus Exposure Irena Tsui, Maria Elisabeth Lope Moreira, Julia D. Rossetto, Zilton Vasconcelos, Stephanie L. Gaw, Luiza M. Neves, Olivia A. Zin, Lorena Haefeli, Joel Carlos Barros Silveira Filho, Saint Clair Gomes Ir, Kristina Adachi, Marcos Vinicius da Silva Pone, Sheila Moura Pone, Jose Paulo Pereira Jr, Rubens Belfort, Vaithilinganja Arumugaswami, Patricia Brasil, Karin Nielsen-Saines and Andrea A. Zin Pediatrics originally published online September 13, 2018; originally published online September 13, 2018;



FIGURE 3

FIGURE 3 Uncommon presentations of ZIKV. A, Eye with microcornea and inferior iris colob coloboma extending into the retina. C, Eye with microcornea and microphthalmi atrophy, severe retinal vessel attenuation, and macular chorioretinal scarring. oloboma. B, Large ON almia. D, Eye with ON

TABLE 2 Eve Abnormalities in All Infants, RTPCR-Positive Mother-Infant Pairs, and RTPCR Unconfirmed Mother-Infant Pairs

	Total 21KV Cases (N = 224). n (%)	RT-PCR-Positive (N = 156), n (%)	RT-PCR Unconfirmed (N = 68), σ (%)
Any eye abnormality	57 (25.4)	32 (20.5)	25 (36.8)
Bilateral disease	51 (22.8)	31 (19.9)	20 (29.4)
Any ON abnormality	44 (19.6)	26 (16.7)	18 (26.5)
ON cupping and/or pallor	35 (15.6)	19 (12.2)	16 (23.5)
ON hypoplasia	12 (5.4)	9 (5.7)	3 (4.4)
0N coloborna	1 (0.5)	1 (0.6)	0.400
Any retina abnormality	37 (16.5)	23 (14.7)	14 (20.6)
Choricretinal atrophy	22 (9.8)	15 (9.6)	7 (10.5)
Pigment mottling	20 (8.9)	12 (7.7)	8 (11.8)
Colobornatous	2 (0.9)	1.(0.6)	1 (1.5)
Severe vessel attenuation	1 (0.5)	0.000	1 (1.5)
Abnormal eye finding with normal physical examination	5 (2.2)	4 (2.6)	1 (3.5)

rus exposure	jacpes
rea A. Zin, MD, PhD,*** hanie L. Gaw, MD, PhJ ena Haefeli, MD,* Joel C cos Vinicius da Silva Po Paulo Pereira Jr, MD,* n Vasconcelos, MSc, P Maria Elisabeth Lopes /	Irena Tsui, MD, ^{1,4} Julia D. Rossetto, MD, PhD,* 3 ^c Luiza M. Neves, MD, ^{4d} Olivia A. Zin, MD, ⁴ Jardos Barros Silveira Filho, MD, ⁶ Kristina Adachi, MD, ⁴ Rubens Befforv, MD, PhD, ⁴ Varialimiliaraja Araumugaswami, PhD, ³ Nubers Refforv, MD, PhD, ⁴ Varialimiliaraja Araumugaswami, PhD, ³ ND,* Patricia Brasil, MD, PhD, ⁴ Karin Nielsen-Saines, MD, MPH, ⁴ Moreira, MD, PhD. ⁴
PURPOSE	To report the findings of a cross-sectional study of visual function in infants with confirmed or suspected antenatal Zika virus (ZIKV) infection seen at a single referral center in Rio de Janeiro.
METHODS	Infants were examined following the ZIKV outbreak period at Instituto Fernandes Fig- ueira/FIOCRUZ. Visual function was considered abnormal if an infant could not fix and follow a standardized high-contrast target (10 cm) by 3-6 months of age. Visual function and associations with structural eye abnormalities, central nervous system (CNS) abnor- malities, microcephaly, and nystagmus were assessed. Sensitivity and specificity of screening criteria for structural eye hormalities was assessed.
RESULTS	A total of 173 infants met inclusion criteria. Abnormal visual function was found in 52 in- fants (30.0%) and was significantly associated with eye abnormalities (40/52; OR = 44.2; 95% CI, 16.6-117.6), CNS abnormalities (50/52; OR = 640.95% CI, 14.7-277.6), micro- cephaly (44/52; OR = 31.5; 95% CI, 12.7-77.8), and nystagmus (26/52; OR = 120.0; 95% CI, 15.6-924.5). Using microcephaly as screening criteria for the detection of eye abnor- malities provided a sensitivity of 88.2% (95% CI, 76.0-96.3) and specificity of 82.8% (95% CI, 75.1-88.9). Using both abnormal visual function and microcephaly increased sensitivity to 100% (95% CI, 92.1-100.0) and decreased specificity to 80.5% (95% CI, 72.5-86.9).
CONCLUSIONS	Infants with suspected antenatal ZIKV infection and reduced visual function should be referred to an ophthalmologist. Visual function assessments are helpful in screening for antenatal ZIKV exposure in resource-limited settings and can identify infants who may benefit from visual habilitation. (J AAPOS 2018;22:452-456)

		Fix-and-follow visual function					
Structural findings	Total no. (%) [n = 173]	Unable, no. (%) [n = 52]	Able, no. (%) [n = 121]	OR (95% CI) /			
Eve abnormality	45 (26)	38 (73)	7 (6)	44.2 (16.6-117.6)	< 0.0001		
Any CNS abnormality	84 (49)	50 (96)	34 (28)	64.0 (14.7-277.6)	< 0.0001		
Microcephaly	62 (36)	44 (85)	18 (15)	31.5 (12.7-77.8)	< 0.0001		
Nystagmus	27 (16)	26 (50)	1 (0.8)	120.0 (15.6-924.5)	< 0.0001		
None of the above	87 (50)	0 (0)	87 (72)	1			

Visual Improvement After Overplus Eyeglasses in Children

with Congenital Zika Infection

Overlapping Spectrum of <u>Retinochoroidal</u> Scarring in Congenital Zika Virus and Toxoplasmosis Infections

Joel Carlos B. Silveira Filho MD^a; Julia D. Rossetto, MD, PhD^{b,c}; Irena Tsui MD^d, Luiza M. Neves MD^b, Lorena Haefeli MD^b; Isabel S.D. Garcia, MD^b, Jocieli Malacarne, PhD^b, Natalia Molleri OT^b, Stephanie L. Gaw; MD, PhD; Olivia A Zin, MD; Marcos Vinicius da Silva Pone, MD^b, PhD; Sheila Moura Pone, MD, PhD^b; Kristina Adachi^d, MD; Jose Paulo Pereira Jr, MD^b; Saint Claire Gomes Jr, PhD^b; Patricia Brasil, MD, PhDⁱ; Karin Nielsen-Saines, MD,MPH^d; Zilton Vasconcelos, MSc, PhD^b; Maria Elisabeth Lopes Moreira, MD, PhD^b; Andrea A. Zin, MD, PhD^b



March 26, 2018			C C Du B.1 A.1	SEARCH A ardia XPOSI Ice H. G. C Farias ¹⁴ , I R. Teixein	RTICLE IC findi Ure to Drofino ^{1,20} *, Maria de Fati a Mendes ^{2,34}	ngs in i Zika vii Sonia R. L. F ma M. P. Leit , Maria Elizat	infants wit rus- a cross ² assos ³⁶ , Raquel V. e ¹⁷ , Sheila M. Pone ⁴ beth L. Moreira ⁵⁴ , Ka	h in uter 5 section ^{c. de Oliveira^{3e}, [†], Marcos V. da S rin Nielsen-Sair}	O Ial study Carla Verona 3. Pone ⁴⁴ , Hele res ⁶⁴
• 1 tł	0.8% ne ra lo se Cardi	6 incidence of s te observed in evere cardiac de ac defects mos	structural the gene efects no at frequer	l heart de eral popu oted. htly foun	efects in 12 ulation. d in infants	20 infants v s whose mo	vith PCR confirme	ed ZIKV expo nd had 2 nd sei	sure, 10 x mester
• C ir Table L	Chara	ion and infants	with abnorm	ormal C	NS imagin	g, but not r	necessarily micro	cephaly.	
• C ir Table 1. Putient	Chara Ses	ion and infants attristics of 13 patients Age at ECHO (days)	with abnorm	INTERNATION	NS imagin dings. Microcephaly	g, but not r	Gestational age (weeks)	21D ficho	Rash-trimester
• C ir Table 1. Putient 1	Chara Ses Girl	ion and infants cteristics of 13 patients Age at ECHO (days) 288	with absorm PCR (m) * Positive	PCR (n) *	NS imagin dings. Microcephaly Yes	g, but not r CNS imaging ^e Positive	Gestational age (weeks)	210 fcbo PDA ^d	Rash-trimester 2nd
• C ir Table 1. Patient	Chara Chara Ses Girl Girl	ion and infants cteristics of 13 patients Age at ECHO (days) 288 220	with abnorm PCR (m) * Positive Positive	PCR (n) ^b Positive Positive	NS imagin dings. Microcephaly Yes No	g, but not r CNS imaging ^e Positive Negative	Gestational age (weeks)	2D-5cbo PDA ⁴ PDA	Rash-trimester 2nd 2nd
• C ir Table 1. Patient 1 2	Chara Ses Girl Girl Boy	ion and infants cteristics of 13 patients Age at ECHO (days) 288 220 132	with abnorm with abnorm PCR (m) * Positive Positive Positive	POSITIVE POSITIVE	NS imagin dings. Microcephaly Yes No No	g, but not r CNS imaging ^e Positive Negative Negative	Gestational age (weeks) 36 40 40	2D-ficho PDA ⁴ PDA VSD ⁴	Rash-trimester 2nd 2nd 2nd
• Circle I. Pable I. Patient	Chara Ses Girl Girl Boy Boy	ton and infants cteristics of 13 patients Age at ECHO (days) 288 220 132 1	with abnorm PCR (m)* Positive Positive Positive Positive Positive	Positive Positive Positive Positive Positive	NS imagin dings. Micrecephaly Yes No No Yes	g, but not r CNS imaging ^d Positive Negative Negative Positive	Gestational age (weeks) 36 40 49 39	2D-Echo PDA ⁴ PDA VSD* PAH ⁷	Rash-trimester 2nd 2nd 1st
• Ciricatoria	Chara Chara Sex Girl Girl Boy Boy Girl	con and infants ceriotics of 13 patients Age at ECHO (days) 288 220 132 1 1 178	with abnorm PCR (m)* Positive Positive Positive Positive Positive Positive	Positive Positive Positive Positive Positive Positive Positive Positive Positive	NS imagin dings. Nicrecephaly Yes No Yes Yes	g, but not r CNS imaging" Positive Negative Positive Positive Positive	Gestational age (weeka) 36 40 49 37	2D Echo PDA ⁴ PDA VSD ⁴ PAH ⁴ PDA	Rash-trimester 2nd 2nd 1st 1st
Cable 1. Patient	Chara Ses Girl Girl Boy Boy Girl Boy	cereities of 13 patients Age at ECHO (days) 288 230 132 1 178 2	with abnorm PCR (m)* Positive Positive Positive Positive Positive Positive Positive Positive	Positive Positive Positive Positive Positive Positive Positive Positive Positive Positive Positive	NS imagin dings. <u>Microcephaly</u> Yes No Yes Yes Yes	g, but not r CNS imaging" Positive Negative Positive Positive Positive	Gestational age (weeks) 36 40 39 37 40	2D-Ecbo PDA ⁴ PDA VSD [*] PDA PDA VSD	Rash-trimester 2nd 2nd 2nd Ist Ist Ist
Cable 1. Patient	Chara Ses Girl Girl Boy Boy Girl Boy Girl Boy Girl	cerietics of 13 patients Age at BCHO (days) 288 132 1 178 2 66	with abnorm with abnorm PCR (m) ⁴ Positive Positive Positive Positive Positive Positive Positive Positive Positive	Positive Positive Positive Positive Positive Positive Positive Positive Positive Positive Positive NA	NS imagin dings. <u>Microcephaly</u> Yes No No No Yes Yes Yes Yes Yes	g, but not r CNS imaging ⁶ Positive Negative Positive Positive Positive Positive Positive Positive	Gestational age (weeks) 36 40 40 37 40 37 40 38	2D-Ecbo PDA ⁴ PDA VSD* PDA VSD* PAH ⁴ PDA VSD ASD ⁴	Rash-trimester 2nd 2nd 2nd 1st 1st 1st 2nd
Table 1. Patient 1 2 3 4 5 6. 7 8	Chara Ses Girl Boy Boy Girl Boy Girl Girl Girl	ion and infants cteristics of 13 patients Age at ECHO (days) 288 220 132 1 178 2 96 228	with abnorm with abnorm PCR (m) ⁴ Positive Positive Positive Positive Positive Positive Positive Negative Neg	In the second se	NS imagin dings. <u>Micrecephaly</u> Yes No Yes Yes Yes Yes No	g, but not r CNS imaging" Positive Negative Positive Positive Positive Positive Positive Positive Positive	Gestational age (weeks) 36 40 37 40 37 40 38 37	20 Ecbo PDA ⁴ PDA ⁴ PDA ⁴ PDA ⁴ PDA ⁴ PDA ⁴ VSD ⁴ ASD ⁴	Rash-trimester 2nd 2nd 2nd 1st 1st 1st 2nd 3sd
Table 1. Patient 1 2 3 4 5 6 7 8 9	Chara Ses Girl Girl Boy Boy Girl Boy Girl Girl Girl Girl Girl	ion and infants Age at ECHO (days) 288 220 132 1 178 2 66 28 22 2 2 2 2 2 2 2 2 2 2 2 2	with abnorm PCR (m)* Positive	eormal C al ECHO fin PCR (n) * Positive Positive Positive Positive Positive Positive NA Positive NA	NS imagin dings. Microcephaly Yes No Yes Yes Yes Yes No Yes	g, but not r CNS imaging" Positive Negative Positive Positive Positive Positive Negative Negative Negative Negative	Gestational age (weeks) 36 40 40 37 40 38 37 35	2D-Ecbo PDA ⁴ PDA VSD [*] PAH ⁴ VSD ASD ⁴ ASD LVH ^k	Rash trimester 2nd 2nd 1st 1st 1st 2nd 2nd 2nd 2nd
Carlot C	Chara Ses Girl Boy Boy Girl Boy Girl Girl Girl Girl Girl Girl Boy	Certificities of 13 patients Age at ECHO (days) 288 220 132 1 1778 2 96 28 2 55	with aborn with abnorn PCR (an) * Positive Positive Positive Positive Positive Positive Positive Positive Positive Positive Positive	al ECHO fin PCR (n) * Positive Positive Positive Positive Positive Positive NA NA NA	NS imagin Micrecephaly Yes No Yes Yes Yes Yes Yes No Yes No No Yes No No Yes No No No No No No No No No No	g, but not r CNS imaging" Positive Negative Positive Positive Positive Negative Negative Negative Negative	Gestational age (weeks) 36 40 40 37 40 37 40 38 37 37 35 39	2D Есію PDA ⁴ PDA YSD ⁴ PDA YSD ⁴ PDA YSD ASD ASD LVH ⁶ ASD	Rash trimester 2nd 2nd 1st 1st 2nd 2sd 2sd 2nd 2nd 2nd
Carlos C	Chara Ses Girl Boy Boy Girl Boy Girl Girl Girl Boy Boy Boy Boy	con and infants contributes of 13 patients Age at ECHO (days) 288 220 132 1 178 2 96 28 2 55 59	with aborn with absorn PCR (m) ⁶ Positive Positive Positive Positive Positive Positive Positive Positive Positive Positive Positive Positive Positive Positive	al ECHO fin PCR (n) ^b Positive Positive Positive Positive Positive NA Positive NA Positive NA Positive NA Positive	NS imagin Microcophaly Yes No No Yes Yes Yes Yes No Yes No No Yes No No No No No No No No No No	g, but not r CNS imaging" Positive Negative Negative Positive Positive Negative Negative Negative Negative Negative	Gestational age (weeks) 36 40 40 37 40 37 40 37 35 39 39 39 39	2D-5cbo PDA ⁴ PDA VSD ⁴ PDA VSD ASD ASD LVH ⁶ ASD VSD VSD	Rash trimester 2nd 2nd 1st 1st 2nd 2nd 2nd 2nd 2nd 2nd 2nd 2nd 2nd 2nd
Critical Table 1. Patient 1 2 3 4 5 6 7 7 8 P 10 11 12	Chara Sex Girl Girl Boy Boy Girl Girl Girl Girl Girl Boy Boy Girl Soy Boy Girl Girl Girl Girl Girl Girl Girl Girl	ion and infants Age at BCHO (days) 288 220 132 1 178 2 96 228 255 91 7	with abnorm with abnorm PCR (m)* Positive Positive Positive Positive Positive Negative Positive	al ECHO fin PCR (n) ^b Positive Positive Positive Positive Positive Positive NA Positive NA Positive NA Positive NA Positive NA	NS imagin Microcephaly Yes No Yes Yes Yes Yes No Yes No No No No No No No No No No	g, but not r CNS imaging ⁶ Positive Negative Positive Positive Positive Positive Negative Negative Negative Negative Negative	Gestational age (weeka) 36 40 40 37 36 37 35 39 33 39 33 39 38	22) Febo PDA ⁴ PDA YSD ⁴ PAH ⁴ PDA YSD ASD ⁴ ASD LVH ⁸ ASD VSD POP, VSD, RSPB ⁷	Rash trimester 2nd 2nd 2nd 1st 1st 2nd 2nd 2nd 2nd 2nd 2nd Not anh





Neurodevelopment of exposed children are not included in most funding opportunities - We may miss the window of opportunity to do something for these children

- We need to consider the neuroplasticity in early life
- Program of early stimulation can improve quality of life

















Apart from 333 neurotypical controls with normal fidgety movements at 3 to 5 months and a Bayley-III score exceeding 85 at their follow-up assessment (100% specificity), normal fidgety movements in the Rio de Janeiro cohort were associated with normal development at age 12 months, with a specificity of 96%. Conversely, the absence of fidgety movements was associated with an adverse outcome at age 12 months, with a sensitivity of 70%.

		Tanable	Munosphaly (n + 1927)	Borsophdy is - 31/*	Canalitation (in + 2018)	Pilota
		Mule. No. (70)	45 (198.3)	19/54.10	180(61.0)	Aut -
No Fidgety Movements	Fidgety Movements	Perform Airth, No. (N)				
		-Diff with generation	10.0		40.8	
		30.35 + 6 mit	843810	L(LA.H	18(01.7)	
		Whether of participant of the time of other time, ed. We				
A CONTRACT OF A CONTRACT. CONTRACT OF A CONTRACT. CONTRACT OF A CONTRACT OF A CONTRACT OF A CONTRACT OF A CONTRACT. CONTRACT OF A CONTRACT. CONTRACT OF A CONTRACT. CONTRACT OF A CONTRACT OF A CONTRACT OF A CONTRACT. CONTRACT OF A CONTRACT OF A CONTRACT. CONTRACT OF A CONTRACT OF A CONTRACT OF A CONTRACT. CONTRACT OF A CONTRACT OF A CONTRACT. CONTRACT OF A CONTRACT. CONTRACT OF A CONTRACT OF A CONTRACT. CONTRACT OF A CONTRACT OF A CONTRACT. CONTRACT OF A CONTRACT. CONTRACT OF A CONTRACT. CONTRACT OF A CONTRACT. CONTRACT OF A CONTRACT OF A CONTRACT. CONTRACT	335	10	JD CR M	19-30.8	44	
ALC: NOT A		14-28	42101.0	813738	88.	
		100	DIRA		44	
	And A CONTRACTOR	April 180, ed. No. 757				
States		9-12	260428	1708.61	129(06.7)	
		12-34	44/57.01	MORTE .	124/62.81	-
	N N N N N N N N N N N N N N N N N N N	12.30	aitm .	405.4	840	
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	1. (N. 10)	fighty meanwrite, Ro.				
	N 4 10 10 10 10 10 10 10 10 10 10 10 10 10	Sec.	March .	1.	101/080	
Contract of the second s	A CONTRACT OF	Reviewed represented	30.00			14
and the second sec	10 Sec. 1	Manual Votes	6211.00	11.738	4	
		Many Departure Lower				
		Rober(UP)(seep)	10 (19 26) (7 26)	16463.8	26.04.00	180
		Springloung of	22 (28.8)		201 (64.4)	140
		Reduced villa for PD	MITTER	10.000	10110-0	- 367
		Institutes No. (N)				
	a line of the line	for elements	15.06.0	10.0	inciria.	
	and a second sec	But are always to	412118	34.0015	87.06.10	1.80
	102 Jul	Monitorial patterns,				
- Maria	haman poo	Howeversets, cheduat				
the second state of the se		Nerrod	10.0	9/8-D	616.0	1.804
	0.4	Reserved	18-8	8040	8(8-0)	1.001
man mi	10 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	Personal patterns, median				
	V V	Sec.	10.8	10-0	104	1.00
	-0.4	Revend .	30-0	10.0	10.5	1.007
		Reserved character, No.				
	a data at h h h h h h h h h h h h h h h h h	Chill State of State	11111		Lange and the	
	Land Martin Martin Martin 10	Comparison of Street	11.08.00	Contract in contract in the second	In cost in	1.000
1 2 3 4 5	0 1 2 3 4 5		ALC: NOT THE OWNER	10.000		
time [e]	Emp [e]	Daniel and		The Part In	and the second s	-
nue fal	ecoe [s]	Comptill synchronized		0.04.0		





Zika spreads rapidly in India, with 94 cases confirmed

By Swati Gupta, CNN () Updated 9:36 AM ET, Wed October 17, 2018

(CNN) — The number of people infected with the Zika virus in India has increased to 94 confirmed cases in the western state of Rajasthan, including 22 pregnant women, as of 17 October.

The first case was confirmed on September 23 and the number of people who have tested positive for the virus in the city of Jaipur has steadily grown since then.

Zika in India

This is India's third outbreak of Zika since 2017, but is by far the biggest.

The first was reported in Ahmedabad in the western Gujarat state around January 2017 with three confirmed cases, according to the World Health Organization.

Months later in July, a second outbreak was reported in the southern state of Tamil Nadu. According to local media reports, one man tested positive for the virus. Both outbreaks were contained.



Rio de Janeiro		California	
Fiocruz Manguinhos:	Fiocruz Inst F Figueira:	UCLA :	
- Patricia Brasil	Maria Elisabete Moreira	Karin Nielsen-Saines	Irena Tsui
- Mayumi Wakimoto	Jose Paulo Pereira Jr.	Kristina Adachi	Trevon Fuller
- Luana Damasceno	Andrea Zin	Genhong Cheng	Umme-Aiman Halai
- Renata Rabello	Zilton Vasconcelos	James D. Cherry	Tara Kerin
-Ana Bispo de Filippis	Dulce Orofino	Carla Janzen	Vaithi Arumugaswami
- Guilherme Calvet	Elyzabeth A. Portari	Kara-Lee Pol	Noriko Salomon
- Jose Henrique Pilotto	Marcos Pone	UCSF: Stephanie Valderra	mos
- Myrna Bonaldo	Sheila Pone	Biomedical Res Inst So CA:	Claudia Raja Gabaglia
- leda Ribeiro	Mitsue Aibe	USC: Jae Jung	
- Ana Bispo		Suan Sin-Foo	
São Paulo	Austria	Weiquiang Chen	
<u>USP</u> : Renata Hasue Carolina <u>Aizawa</u> Fernanda Genovesi	University of Graz: - Peter Marschik - Christa Einspeller	MUITO OBRIGADA!	ZKA
National Institute of Allergy and Infectious Diseases	FAPERJ	@CNP q	
	NIH National Eye Institu	te BILL&MELINDA GATES foundation	Thrasher Research Fur



